Jinghan Hua,Zhe Wang,Xiaoxun Cheng et al.
Jinghan Hua et al.
Acquired drug resistance is a main factor contributing to cancer therapy failure and high cancer mortality, highlighting the necessity to develop novel intervention targets. Circular RNAs (circRNAs), an abundant class of RNA molecules with ...
Exosomal miR-92b-5p regulates N4BP1 to enhance PTEN mono-ubiquitination in doxorubicin-resistant AML [0.03%]
外泌体miR-92b-5p通过调节N4BP1促进PTEN单泛素化在多柔比星耐药急性髓系白血病中的作用
Qianyuan Li,Jie Cheng,Danni Qin et al.
Qianyuan Li et al.
Aim: Doxorubicin, pivotal for acute myeloid leukemia (AML) treatment, often succumbs to resistance, impeding therapeutic success. Although exosomal transfer is linked to chemoresistance, the detailed role of exosomal miRNAs in doxorubicin r...
The epigenetic mechanisms involved in the treatment resistance of glioblastoma [0.03%]
与胶质母细胞瘤治疗抵抗有关的表观遗传机制
Aanya Shahani,Hasan Slika,Ahmad Elbeltagy et al.
Aanya Shahani et al.
Glioblastoma (GBM) is an aggressive malignant brain tumor with almost inevitable recurrence despite multimodal management with surgical resection and radio-chemotherapy. While several genetic, proteomic, cellular, and anatomic factors inter...
Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer types [0.03%]
解译BRAF突变：分子见解跨癌种克服治疗耐药性
Caterina Perfetto,Marianna Aprile,Simona Cataldi et al.
Caterina Perfetto et al.
Aim: As intrinsic resistance - often driven by concurrent genomic alterations in tumor suppressor genes or oncogenes - remains a major challenge in oncology, this work aimed to comprehensively analyze BRAF somatic alterations across cancer ...
Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing [0.03%]
抗体偶联药物在乳腺癌治疗中的耐药机制及序贯治疗作用
Émilie Audrey Larose,Xinying Hua,Silin Yu et al.
Émilie Audrey Larose et al.
Antibody-drug conjugates (ADCs) are a transformative approach in breast cancer therapy, offering targeted treatment with reduced toxicity by selectively delivering cytotoxic agents to cancer cells. While ADCs like trastuzumab emtansine (T-D...
Strategies to combat cancer drug resistance: focus on copper metabolism and cuproptosis [0.03%]
应对癌症药物抵抗的策略：着重铜代谢和铜依赖性细胞死亡研究
Leyi Yao,Baoyi Jiang,Dacai Xu
Leyi Yao
Cancer cells often develop tolerance to chemotherapy, targeted therapy, and immunotherapy drugs either before or during treatment. The significant heterogeneity among various tumors poses a critical challenge in modern cancer research, part...
Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways [0.03%]
天然倍半萜内酯抗肿瘤研究进展：通过调节关键信号通路克服耐药性研究进展
Chi Teng,Jia-Wen Chen,Li-Sha Shen et al.
Chi Teng et al.
Cancer remains a significant global health challenge, with current chemotherapeutic strategies frequently limited by the emergence of resistance. In this context, natural compounds with the potential to overcome resistance have garnered con...
Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma [0.03%]
肿瘤微环境在肝细胞癌免疫检查点阻断疗法抵抗中的复杂作用
Yi-Zhe Zhang,Yunshu Ma,Ensi Ma et al.
Yi-Zhe Zhang et al.
Hepatocellular carcinoma (HCC) remains a serious threat to global health, with rising incidence and mortality rates. Therapeutic options for advanced HCC are quite limited, and the overall prognosis remains poor. Recent advancements in immu...
Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance [0.03%]
代谢的十字路口：解开胃肠癌药物抵抗中的免疫细胞动态过程
Chahat Suri,Babita Pande,Lakkakula Suhasini Sahithi et al.
Chahat Suri et al.
Metabolic reprogramming within the tumor microenvironment (TME) plays a critical role in driving drug resistance in gastrointestinal cancers (GI), particularly through the pathways of fatty acid oxidation and glycolysis. Cancer cells often ...
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches [0.03%]
克服去势抵抗性前列腺癌中的药物抗性：当前的机制及新兴的治疗方法
Adam Khorasanchi,Feng Hong,Yuanquan Yang et al.
Adam Khorasanchi et al.
Metastatic castration-resistant prostate cancer (mCRPC) is driven by a complex network of resistance mechanisms against standard-of-care therapies, resulting in poor long-term outcomes. This review offers a uniquely comprehensive and integr...